Does Valganciclovir Hydrochloride (Valcyte) Provide Effective Prophylaxis Against Cytomegalovirus Infection in Liver Transplant Recipients?
- 1 September 2005
- journal article
- Published by Elsevier in Transplantation Proceedings
- Vol. 37 (7) , 3182-3186
- https://doi.org/10.1016/j.transproceed.2005.07.032
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipientsTransplantation, 2003
- Preemptive Use of Oral Ganciclovir to Prevent Cytomegalovirus Infection in Liver Transplant Patients: A Randomized, Placebo‐Controlled TrialThe Journal of Infectious Diseases, 2002
- CYTOMEGALOVIRUS PP65 ANTIGEN-GUIDED PREEMPTIVE THERAPY WITH GANCICLOVIR IN SOLID ORGAN TRANSPLANT RECIPIENTS: A PROSPECTIVE, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDYTransplantation, 2001
- GanciclovirDrugs, 2001
- EFFECT OF ORAL ACYCLOVIR OR GANCICLOVIR THERAPY AFTER PREEMPTIVE INTRAVENOUS GANCICLOVIR THERAPY TO PREVENT CYTOMEGALOVIRUS DISEASE IN CYTOMEGALOVIRUS SEROPOSITIVE RENAL AND LIVER TRANSPLANT RECIPIENTS RECEIVING ANTILYMPHOCYTE ANTIBODY THERAPY1Transplantation, 1998
- GanciclovirDrugs, 1998
- Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipientsThe Lancet, 1997
- PROPHYLAXIS OF CYTOMEGALOVIRUS INFECTION IN LIVER TRANSPLANTATIONTransplantation, 1997
- CMV Infection of transplant RecipientsJournal of Hepatology, 1996
- High-Dose Acyclovir Compared with Short-Course Preemptive Ganciclovir Therapy To Prevent Cytomegalovirus Disease in Liver Transplant RecipientsAnnals of Internal Medicine, 1994